Tricuspid Regurgitation correction, because our patient’s worth it

Abstract Tricuspid regurgitation (TR), once considered a passive marker of advanced cardiac disease, is increasingly recognized as an independent contributor to morbidity, mortality, and healthcare burden. Recent evidence, including the pivotal TRILUMINATE trial or Tri-Fr and supporting cost-effectiveness models, suggest that the correction of TR—particularly with transcatheter edge-to-edge repair (TEER) systems—can significantly improve patient outcomes and offer good value for money in European healthcare settings. This article explores the clinical rationale and economic imperative for considering TR as a modifiable and actionable target in modern cardiology.